Tolanase en es it fr

Tolanase Brand names, Tolanase Analogs

Tolanase Brand Names Mixture

  • No information avaliable

Tolanase Chemical_Formula


Tolanase RX_link

Tolanase fda sheet

Tolanase FDA

Tolanase msds (material safety sheet)

Tolanase MSDS

Tolanase Synthesis Reference

No information avaliable

Tolanase Molecular Weight

390.513 g/mol

Tolanase Melting Point

No information avaliable

Tolanase H2O Solubility

Insoluble at 25°C

Tolanase State


Tolanase LogP


Tolanase Dosage Forms

Solution for injection (supplied in 20 mL multi-use vials in four strengths, containing 1 mg/mL, 2.5 mg/mL, 5 mg/mL or 10 mg/mL of treprostinil)

Tolanase Indication

For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.

Tolanase Pharmacology

Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed.

Tolanase Absorption

Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.

Tolanase side effects and Toxicity

Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.

Tolanase Patient Information

Tolanase Organisms Affected

Humans and other mammals